<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/shutterstock_2505799329-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/shutterstock_2505799329-430x241.jpg"/>
                                    
                                    <figcaption>Otsuka gains exclusive rights to develop and market the therapy for retinal vascular conditions. Credit: Mangza2029/Shutterstock.com.
</figcaption>
                                </figure>
                            </div>
                                             
     
<p>4D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment for wet age-related macular degeneration (wet AMD) and diabetic macular oedema, across Asia-Pacific (APAC), including Japan.</p>



<p>4D-150 delivers a prolonged, sustained release of anti-vascular endothelial growth factor (anti-VEGF) from the retina with one intravitreal injection.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - AIV-007 in Diabetic Macular Edema </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - AIV-007 in Wet (Neovascular / Exudative) Macul... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The partnership involves an upfront payment of $85m from Otsuka to 4DMT, with an anticipated cost-sharing commitment of a minimum of $50m over the three years to 2028 to support worldwide development.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Beyond the initial payments, 4DMT will receive up to $336m in potential milestone payments linked to regulatory and commercial achievements, as well as tiered royalties based on net sales within Otsuka’s territories.</p>



<p>Otsuka gains exclusive rights to develop and market the therapy for retinal vascular conditions in Australia, China and Japan, as well as other APAC nations.</p>



<p>The company will also oversee regulatory filings and marketing operations in its licensed territories.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>4DMT will lead the global Phase III clinical programme for the therapy, including sites within the APAC region.</p>



<p>Opening of clinical sites in the region as part of the global Phase III 4FRONT-2 trial for wet AMD is anticipated by the end of 2025, with Japanese sites anticipated to commence in January 2026.</p><div id="slot-two"></div>



<p>4DMT CEO and co-founder David Kirn stated: “We are thrilled to announce this strategic partnership with Otsuka, a leading global pharmaceutical company with a strong presence in the APAC region, reflecting our shared long-term commitment to improving outcomes for patients with retinal vascular diseases.</p>



<p>“This partnership is a key pillar of our global strategy, with 4DMT continuing to lead Phase III clinical trial and manufacturing activities globally, in addition to pre-commercial and commercial activities outside the APAC region.”</p>



<p>4DMT retains complete rights to develop and market 4D-150 outside APAC, including in Latin America, Europe and the US.</p>



<p>In May 2025, 4D-150 secured regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration for use in diabetic macular oedema.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

FDMT

<p>4D Molecular Therapeutics (4DMT) has entered an exclusive license agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment for retinal vascular conditions, including wet AMD and diabetic macular edema, in the Asia-Pacific region. Otsuka will pay $85 million upfront and commit at least $50 million for development costs through 2028, with potential milestone payments of up to $336 million. 4DMT will lead the global Phase III clinical program, while retaining rights to develop and market the therapy outside APAC.</p>

4DMT and Otsuka to advance eye disease treatment in APAC